Duration of humoral immunity to common viral and vaccine antigens.

By Ian J. Amanna, N. Carlson, M. Slifka. New England Journal of Medicine, 2007

1,250 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology

View Paper: https://www.semanticscholar.org/paper/a9c1b4b607c4ca98bed55360758381f93d33022e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. E. Wherry
2. X. Castellsagué

In Immunology

1. R. Aspinall
2. C. Siegrist
3. A. Sher
4. R. Seder
5. R. Coffman
6. E. Wherry
7. Rafi Ahmed
8. A. Schietinger

Citations in the corpus

• Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination (2021, background): “has found that antibodies and memory B cells correlate for some vaccines or antigens, but do not correlate for many others (34).”
• Expanding roles for CD4+ T cells in immunity to viruses (2012, neutral): “Antibody-mediated protection can be extraordinarily long-live”
• From Vaccines to Memory and Back (2010, neutral): “Recent studies identified signaling pathways that appear to be involved in the differentiation of memory stem cells as well as drugs that favor the generation of T CM cells (Araki et al., 2009; Gattinoni et al., 2009; Pearce et al., 2009).”
• B-cell responses to vaccination at the extremes of age (2009, background): “Antibody responses to viruses, such as varicella-zoster, measles and mumps, have half-lives of 50 years or more, whereas antibody responses to non-replicating protein antigens, such as tetanus and diphtheria toxins, decline with half-lives of 10–20 year”
• A review of clinical trials of human papillomavirus prophylactic vaccines. (2012, background): “The stable long-term antibody titers observed after L1 VLP vaccination are reminiscent of the antibody responses to virion proteins in live virus vaccines that routinely provide life-long protection [85].”
• Vaccine Adjuvants: Putting Innate Immunity to Work (2010, background): “Antibody responses to many current vaccines are long-lived and require infrequent or no additional boosting to sustain protection (Amanna et al., 2007).”